Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
IPO Year: 2018
Exchange: NYSE
Website: elanco.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/19/2024 | $17.00 → $15.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/5/2024 | $13.00 → $20.00 | Hold → Buy | Stifel |
| 12/19/2023 | $17.00 | Buy | Jefferies |
| 12/15/2023 | $16.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/7/2023 | $18.00 | Outperform | Exane BNP Paribas |
| 4/20/2023 | $14.00 | Equal Weight → Overweight | Barclays |
| 8/18/2022 | $37.00 → $22.00 | Overweight → Equal-Weight | Morgan Stanley |
| 8/16/2022 | $28.00 → $24.00 | Overweight → Neutral | JP Morgan |
| 7/21/2022 | $32.00 → $19.00 | Buy → Sell | Goldman |
| 7/12/2022 | $22.00 | Neutral | Piper Sandler |
GREENFIELD, Ind., Nov. 15, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Speke Ltd., was under trading administration, a formal insolvency process in the United Kingdom. As previously shared on the Company's third quarter 2024 earnings call, the Speke facility plays a vital role for Elanco in producing a number of farm animal product lines, representing approximately $160 million to $180 million in annual farm animal revenue, primarily
Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen
GREENFIELD, Ind., Oct. 10, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2024 financial results on Thursday, November 7, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de
Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect against six parasites, including fleas, ticks, heartworms, roundworms, hookwormsii and three different species of tapeworm that other brands skip creating a gap in coverageiiiWarming temperatures and changing consumer habits have increased parasite pressure and spread across geographies, bringing with them increased public health risk.Experts recommend monthly treatment for zoonotic parasitesiv, like Echinococcus granulosus, a type of tapeworm.Credelio Quattro launch expected in first quarter of 2025GREENFIELD, Ind., Oct. 7, 2024 /PRNewswire/ -- Ela
U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitisElanco enters the estimated $1.7 billion global canine dermatology market, highly accretive to existing portfolioIn a head-to-head study, Zenrelia was shown to be at least as effective as the market incumbent JAK inhibitor at the primary end point, with an additional endpoint at which Zenrelia got 77% of dogs to clinical remission of itch, compared to 53% of dogs treated with Apoquel® (oclacitinib tablet)1*Zenrelia launch begins in U.S. with Elanco now taking orders; product expected to ship in coming daysGREENFIELD, Ind., Sept. 19, 2024 /PRNewswire/ -- Elanco Anim
GREENFIELD, Ind., Sept. 13, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today provided an update on its relationship with contract manufacturing supplier, TriRx Speke Ltd (TriRx). TriRx today entered into trading administration, a formal insolvency process in the United Kingdom designed to help companies facing severe financial challenges regain stability. Administrators from FTI Consulting LLP have been appointed. Elanco has a long-term supply agreement with TriRx to manufacture select farm animal products at the Speke site. Elanco is working constructi
GREENFIELD, Ind., Aug. 28, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will attend the Morgan Stanley 22nd Annual Global Healthcare Conference, September 4-5, 2024. Jeff Simmons, President and CEO, and Todd Young, executive vice president and CFO, will participate in a fireside chat on Thursday, September 5 at 3:20 p.m. ET. A live audio webcast will be available in the "Events and Presentations" section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT ELANCOElanco Animal Health Incorporated (NYSE:ELAN) is a global
Company's broad spectrum parasiticide on-track for October U.S. approval and first quarter 2025 launch GREENFIELD, Ind., Aug. 20, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its review of all major and minor technical sections for Credelio Quattro, and the final 60-day administrative review is underway. "This is an exciting time at Elanco as we deliver a robust innovation portfolio that we believe will help transform animal care with solutions that go beyond today's market leaders,
Study finds that the aggressive lone star tick is no match for Credelio GREENFIELD, Ind., Aug. 15, 2024 /PRNewswire/ -- Parasites & Vectors, a leading peer-reviewed journal focused on parasites and vector-borne pathogens published the results of a head-to-head study demonstrating that Credelio, a prescription flea and tick protection product from Elanco Animal Health, has the fastest initial speed of tick kill in just 12 hours and sustains that advantage throughout the dosing interval.1,2,3 According to the Centers for Disease Control (CDC), during 2019 – 2022, state and local health departments reported more than 45,000 human cases of tickborne disease to CDC.4 The Companion Animal Parasite
GREENFIELD, Ind., July 18, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2024 financial results on Thursday, August 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/def
Merck & Company (NYSE:MRK) completed the acquisition of the aquaculture business part of Elanco Animal Health (NYSE:ELAN). What Happened: Elanco completed the sale for about $1.3 billion in cash. Upon completion, Elanco expects to have between $1.05 billion and $1.1 billion available for debt paydown. “With the completion of this acquisition, we are well positioned within the aquaculture industry with a robust and comprehensive portfolio across warm water, cold water, vaccines, anti-parasitic treatments, water supplements and nutrition,” said Rick DeLuca, president of Merck Animal Health. In addition, Merk Animal Health now owns products including CLYNAV, a DNA-based vaccine that pr
On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners named Citigroup Inc. (NYSE:C), which is scheduled to release earnings on Friday. “The market believes it’s going to be good, so do I,” he said. Analysts expect Citigroup to report quarterly earnings at $1.41 per share, up from $1.33 per share in the year-ago period. The bank is projected to report revenue of $20.08 billion, compared to $19.44 billion in the year-earlier quarter. Stephanie Link of Hightower picked Elanco Animal Health Incorporated (NYSE:ELAN). “I like it on the buy because they have a lot of new products coming,” she added. On June 27, Elanco Animal Health released updates to the expected FDA
- CNBC
During the last three months, 4 analysts shared their evaluations of Elanco Animal Health (NYSE:ELAN), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 2 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 0 0 0 2M Ago 0 1 1 0 0 3M Ago 0 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $19.75, with a high estimate of $23.00 and a low estimate of $16.00. Holding firm without variat
Piper Sandler analyst David Westenberg maintains Elanco Animal Health (NYSE:ELAN) with a Neutral and lowers the price target from $19 to $16.
Barclays analyst Balaji Prasad maintains Elanco Animal Health (NYSE:ELAN) with a Overweight and lowers the price target from $23 to $21.
Elanco Animal Health Incorporated (NYSE:ELAN) stock is tumbling as the company released updates to the expected FDA approval timelines for Zenrelia and Credelio Quattro. Zenrelia is a JAK Inhibitor that controls pruritus and atopic dermatitis in dogs. For Zenrelia, the FDA confirmed that all major technical sections (Effectiveness, Safety and Chemistry, Manufacturing, and Controls (CMC)) are complete as of late June. For the minor technical section for labeling, earlier this week, the company aligned with the FDA on the language and expects to receive the completion letter by mid-July. The 60-day final administrative review will follow, placing expected approval late in the third
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
GREENFIELD, Ind., Nov. 15, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Speke Ltd., was under trading administration, a formal insolvency process in the United Kingdom. As previously shared on the Company's third quarter 2024 earnings call, the Speke facility plays a vital role for Elanco in producing a number of farm animal product lines, representing approximately $160 million to $180 million in annual farm animal revenue, primarily
GREENFIELD, Ind., Oct. 10, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2024 financial results on Thursday, November 7, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de
U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitisElanco enters the estimated $1.7 billion global canine dermatology market, highly accretive to existing portfolioIn a head-to-head study, Zenrelia was shown to be at least as effective as the market incumbent JAK inhibitor at the primary end point, with an additional endpoint at which Zenrelia got 77% of dogs to clinical remission of itch, compared to 53% of dogs treated with Apoquel® (oclacitinib tablet)1*Zenrelia launch begins in U.S. with Elanco now taking orders; product expected to ship in coming daysGREENFIELD, Ind., Sept. 19, 2024 /PRNewswire/ -- Elanco Anim
GREENFIELD, Ind., July 18, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2024 financial results on Thursday, August 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/def
First Quarter 2024 Financial ResultsRevenue of $1,205 millionReported Net income of $32 million, Adjusted Net income of $167 millionAdjusted EBITDA of $294 million, or 24.4% of RevenueReported EPS of $0.06, Adjusted EPS of $0.34 Net leverage ratio of 6.1x Adjusted EBITDAYear over year growth rates are meaningfully impacted by a shift in customer purchasing related to the ERP Blackout in 2023, with an estimated $90 to $110 million of revenue shift from the second quarter of 2023 into the first quarter of 2023Updating full year 2024 financial guidance to reflect first quarter outperformance offset by expected unfavorable impact of foreign exchange rates:Revenue of $4,460 to $4,515 million, con
GREENFIELD, Ind., April 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau
GREENFIELD, Ind., Feb. 8, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2023 financial results on Monday, February 26, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website on our events and presentations page. A repla
Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2023 financial results on Tuesday, November 7, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website on our events and presentations page. A replay will also be available on the website shortly following the call. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated
Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2023 financial results on Monday, August 7, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website on our events and presentations page. A replay will also be available on the website shortly following the call. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated t
First Quarter 2023 Financial Results Revenue of $1,257 million, including an estimated $90-$110 million benefit from customer purchasing shifted from the second quarter into the first as a result of ERP system commercial ordering blackout period for legacy Bayer Animal Health products in April Reported Net Income of $103 million, Adjusted Net Income of $220 million Adjusted EBITDA of $379 million or 30.2% of Revenue Reported EPS of $0.21, Adjusted EPS of $0.45 Net leverage ratio of 5.4x Adjusted EBITDA Raising the bottom end of full year 2023 guidance ranges to reflect current assumptions: Revenue of $4,310 to $4,400 million Reported Net Loss of $(134) to $(98) mil
Morgan Stanley downgraded Elanco Animal Health from Overweight to Equal-Weight and set a new price target of $15.00 from $17.00 previously
Stifel upgraded Elanco Animal Health from Hold to Buy and set a new price target of $20.00 from $13.00 previously
Jefferies initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $17.00
Morgan Stanley upgraded Elanco Animal Health from Equal-Weight to Overweight and set a new price target of $16.00
Exane BNP Paribas initiated coverage of Elanco Animal Health with a rating of Outperform and set a new price target of $18.00
Barclays upgraded Elanco Animal Health from Equal Weight to Overweight and set a new price target of $14.00
Morgan Stanley downgraded Elanco Animal Health from Overweight to Equal-Weight and set a new price target of $22.00 from $37.00 previously
JP Morgan downgraded Elanco Animal Health from Overweight to Neutral and set a new price target of $24.00 from $28.00 previously
Goldman downgraded Elanco Animal Health from Buy to Sell and set a new price target of $19.00 from $32.00 previously
Piper Sandler initiated coverage of Elanco Animal Health with a rating of Neutral and set a new price target of $22.00
8-K - Elanco Animal Health Inc (0001739104) (Filer)
10-Q - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
10-Q - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen
New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner brings significant global experience in both the animal health and broader healthcare industries. She has held senior leadership positions at IDEXX Labora
GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE:ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts. "Shiv's ability to deliver strategic value to Elanco in the short term serving as our interim general counsel combined with her robust experience made it clear that she was the right person for this role," said Jeff Simmons,
Calling all Veterinarians and Pet Lovers - Take the "Defend Puppies. Defeat Parvo." Pledge Today to Save Puppies from Deadly Canine Parvovirus GREENFIELD, Ind., Jan. 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today launched the first-of-its-kind, multi-year campaign to save 1 million puppies from unnecessary death from the highly contagious canine parvovirus (parvo). The Defend Puppies. Defeat Parvo. mission seeks to conquer a virus that, without timely and aggressive care, has a mortality rate as high as 91%1. An estimated 900 dogs are diagnosed with parvo daily2 in the U.S. – mostly unvaccinated puppies. Yet Elanco research revealed only 44% of dog owners know
Ziff Davis, Inc. (NASDAQ:ZD), today announced the appointment of Kirk McDonald to its Board of Directors, effective November 15, 2023. McDonald is a highly accomplished executive with extensive experience and a career spanning more than three decades in media, technology, and advertising. "We are thrilled to welcome Kirk to our Board of Directors," said Ziff Davis Board Chair Sarah Fay. "As an industry veteran known for his business leadership, he will be an asset to Ziff Davis." McDonald serves as CEO of GroupM North America, a leading media investment agency. He announced that he will leave the role at year end. Prior to this, he was Chief Business Officer of Warner Media's Xandr when
Tim Bettington joins Elanco as EVP Corporate Strategy and Market Development Elanco Animal Health (NYSE:ELAN) announced today the appointment of Tim Bettington as the company's executive vice president Corporate Strategy and Market Development. He will join Elanco's executive committee on March 20. As Elanco shifts from the separation and stand up of the independent company and the integration of the Bayer Animal Health acquisition to an increasing focus on delivering its next era of innovation and growth, Bettington's expertise complements the company's existing commercial leadership team. In his role, Bettington will be responsible for corporate strategy and market development, focused
TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po
Pietro Satriano Steps Down as CEO and Will Not Stand for Re-election as Director at 2022 Annual Meeting of Shareholders Robert M. Dutkowsky to Serve as Executive Chair and Andrew Iacobucci to Serve as Interim CEO Board Has Commenced Search for Permanent CEO Appoints James J. Barber, Jr., Scott D. Ferguson and David A. Toy to Board Pursuant to Agreement with Sachem Head Reaffirms Fiscal Year 2022 Guidance US Foods Holding Corp. (NYSE:USFD) ("US Foods" or the "Company"), one of the largest foodservice distributors in the United States, today announced a transition of its Chief Executive Officer. The Company also announced changes to its Board of Directors in connection with a cooperation
Elanco Animal Health (NYSE:ELAN) announced today the appointment of Rajeev (Bobby) Modi as the company's executive vice president U.S. Pet Health and Global Digital Transformation. He will join the company on March 14 and will serve on the company's executive committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220222005316/en/Elanco welcomes Bobby Modi as executive vice president U.S. Pet Health and Global Digital Transformation. With a track record of building and growing consumer brands and a history within the pet industry, Bobby is positioned to lead and grow our business as we continue to transform our digital strategy
Brings experience in managing global innovation portfolios and business development to Scout BioExecutive leadership experience across both animal and human health PHILADELPHIA, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Scout Bio, a biotechnology company developing therapeutic proteins and one-time AAV gene therapies for major chronic pet health conditions announced it had appointed Aaron Schacht to its Board of Directors. Mr. Schacht is a deeply experienced life sciences executive with management expertise across a wide range of functions and will work with Scout Bio to execute its strategic development as a veterinary biopharma pioneer. "Scout Bio's approach to the innovation and delivery of e
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
3 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)